UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 2)

NEOLEUKIN THERAPEUTICS, INC.

(Name of Issuer) Common Stock, \$0.000001 par value (Title of Class of Securities) 64049K104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) heck the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Af 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the tots).		·
(Title of Class of Securities) 64049K104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) heck the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for a subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange A if 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the subject to all other provision		(Name of Issuer)
Guernher 31, 2022		Common Stock, \$0.000001 par value
(CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) heck the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for your subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange A 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the subject to all other provisions of the Act (however, see the subject to the s		(Title of Class of Securities)
December 31, 2022 (Date of Event Which Requires Filing of this Statement) heck the appropriate box to designate the rule pursuant to which this Schedule is filed: □ Rule 13d-1(b) □ Rule 13d-1(c) □ Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for your subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange A 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the subject to th		64049K104
(Date of Event Which Requires Filing of this Statement) heck the appropriate box to designate the rule pursuant to which this Schedule is filed: □ Rule 13d-1(b) □ Rule 13d-1(c) □ Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange At 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the		(CUSIP Number)
heck the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange A in 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the		December 31, 2022
Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for a subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange A 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the subject to the subject	(Date o	f Event Which Requires Filing of this Statement)
Rule 13d-1(c) Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for a subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange A ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the	heck the appropriate box to designate the rule pursuan	t to which this Schedule is filed:
Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange A ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the subject to	☑ Rule 13d-1(b)	
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange A ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the	☐ Rule 13d-1(c)	
by subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange A ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the subject to the subject t	☐ Rule 13d-1(d)	
1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the		
	1934 ("Act") or otherwise subject to the liabilities	

CUSIP	No. 64049K104	4			
1	Name of Reporting Person				
	Redmile Gro	up, LL	C		
2	Снеск тне Арг	PROPRIAT	E BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)		
	(A) □				
	(A) □ (B) □				
3	SEC Use Only				
4	CITIZENSHIP OR	PLACE C	OF ORGANIZATION		
	Delaware				
		5	Sole Voting Power		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH			0		
		6	Shared Voting Power		
			3,030,566 ⁽¹⁾		
	PORTING SON WITH	7	Sole Dispositive Power		
TERSON WITH			0		
		8	Shared Dispositive Power		
			3,030,566 ⁽¹⁾		
9	Aggregate Amount Beneficially Owned by Each Reporting Person				
	3,030,566 (1)				
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
11	Percent of Class Represented by Amount in Row (9)				
	6.9%(2)				
12	Type of Reporting Person (See Instructions)				
	IA, OO				

⁽¹⁾ Redmile Group, LLC's beneficial ownership of the Issuer's common stock ("Common Stock") is comprised of 1,850,566 shares of Common Stock owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Redmile Group, LLC may also be deemed to beneficially own 1,180,000 shares of Common Stock issuable upon exercise of certain Warrants to Purchase Common Stock (the "Warrants").

⁽²⁾ Percentage based on: (i) 42,594,602 shares of Common Stock outstanding as of November 11, 2022, as reported by the Issuer in its Form 10-Q for the period ending September 30, 2022 and filed with the SEC on November 14, 2022 (the "Form 10-Q"), plus (ii) 1,180,000 shares of Common Stock issuable upon exercise of certain of the Warrants.

CUSIP	No. 64049K10	4		
1	Name of Repo	RTING P	ERSON	
	Jeremy C. G	reen		
2	Снеск тне Ар	PROPRIAT	TE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
	(A) 🗆			
	(B) □			
3	SEC Use Only			
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	United Kingdom			
		5	Sole Voting Power	
			0	
	MBER OF	6	Shared Voting Power	
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH			3,030,566 ⁽³⁾	
			3,030,566	
		7	Sole Dispositive Power	
			0	
		8	Shared Dispositive Power	
			(2)	
			3,030,566 ⁽³⁾	
9	Aggregate Amount Beneficially Owned by Each Reporting Person			
	3,030,566 ⁽³⁾			
10				
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) \square			
11	Percent of Class Represented by Amount in Row (9)			
	6.9% ⁽⁴⁾			
12	Type of Reporting Person (See Instructions)			
	IN, HC			

⁽³⁾ Jeremy C. Green's beneficial ownership of Common Stock is comprised of 1,850,566 shares of Common Stock owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Mr. Green may also be deemed to beneficially own 1,180,000 shares of Common Stock issuable upon exercise of the Warrants.

⁽⁴⁾ Percentage based on: (i) 42,594,602 shares of Common Stock outstanding as of November 11, 2022, as reported by the Issuer in its Form 10-Q, plus (ii) 1,180,000 shares of Common Stock issuable upon exercise of certain of the Warrants.

Item 1.

(a) Name of Issuer

Neoleukin Therapeutics, Inc.

(b) Address of Issuer's Principal Executive Offices

188 East Blaine Street, Suite 450 Seattle, Washington 98102

Item 2.

(a) Names of Persons Filing

Redmile Group, LLC Jeremy C. Green

(b) Address of Principal Business office or, if None, Residence

Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129

Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001

(c) Citizenship

Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom

(d) Title of Class of Securities

Common Stock, \$0.000001 par value

(e) CUSIP Number

64049K104

Item 3.	. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:				
	(a)		Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);		
	(b)		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);		
	(c)		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);		
	(d)		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);		
	(e)	\boxtimes	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);		
	(f)		An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);		
	(g)	\boxtimes	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);		
	(h)		A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);		
	(i)		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);		
	(j)		A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);		
	(k)		Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J) please specify the type of institution:		
Item 4.	Ownership.				
	(a)	A	mount beneficially owned:		
			edmile Group, LLC – 3,030,566 * eremy C. Green – 3,030,566 *		
	(b)	Pe	ercent of class:		
			edmile Group, LLC – 6.9%** eremy C. Green – 6.9%**		
	(c)	N	umber of shares as to which Redmile Group, LLC has:		
		(i)	Sole power to vote or to direct the vote:		
			0		
		(ii	i) Shared power to vote or to direct the vote:		
			3,030,566 *		

(iii) Sole power to dispose or to direct the disposition of:

0

(iv) Shared power to dispose or to direct the disposition of:

3,030,566 *

Number of shares as to which Jeremy C. Green has:

(i) Sole power to vote or to direct the vote:

0

(ii) Shared power to vote or to direct the vote:

3,030,566 *

(iii) Sole power to dispose or to direct the disposition of:

0

(iv) Shared power to dispose or to direct the disposition of:

3,030,566 *

- * Redmile Group, LLC's and Jeremy C. Green's beneficial ownership of the Issuer's Common Stock is comprised of 1,850,566 shares of Common Stock owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Redmile Group, LLC and Mr. Green may also be deemed to beneficially own 1,180,000 shares of Common Stock issuable upon exercise of the Warrants.
- ** Percentage based on: (i) 42,594,602 shares of Common Stock outstanding as of November 11, 2022, as reported by the Issuer in its Form 10-Q, plus (ii) 1,180,000 shares of Common Stock issuable upon exercise of certain of the Warrants.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following \Box

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

N/A.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

See the response to Item 4.

Item 8. Identification and Classification of Members of the Group.

N/A

Item 9. Notice of Dissolution of Group.

N/A

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2023

Redmile Group, LLC

By: /s/ Jeremy C. Green

Name: Jeremy C. Green Title: Managing Member

/s/ Jeremy C. Green

Jeremy C. Green

Joint Filing Agreement

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the "Schedule 13G") relating to the Common Stock, \$0.00001 par value per share, of Neoleukin Therapeutics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.

The undersigned further agree that each party hereto is responsible for the timely filing of the Schedule 13G, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has a reason to believe that such information is inaccurate.

It is understood and agreed that a copy of this Joint Filing Agreement shall be attached as an exhibit to the Schedule 13G, filed on behalf of each of the parties hereto.

IN WITNESS WHEREOF, each of the undersigned has executed this Joint Filing Agreement as of the 14th day of February, 2023.

REDMILE GROUP, LLC

/s/ Jeremy C. Green

Name: Jeremy C. Green Title: Managing Member

/s/ Jeremy C. Green

JEREMY C. GREEN